Abstract:Background The RNA-binding protein Musashi-2 (MSI2) has been implicated in the tumorigenesis and tumor progression of some human cancers. MSI2 has also been reported to suppress tumor epithelial-to-mesenchymal transition (EMT) progression in breast cancer, and low MSI2 expression is associated with poor outcomes for breast cancer patients; however, the underlying mechanisms have not been fully investigated. This study investigated the expression and phenotypic functions of two major alternatively spliced MSI2 isoforms (MSI2a and MSI2b) and the potential molecular mechanisms involved in triple-negative breast cancer (TNBC) progression. Methods The Illumina sequencing platform was used to analyze the mRNA transcriptomes of TNBC and normal tissues, while quantitative reverse transcription-polymerase chain reaction and immunohistochemistry validated MSI2 isoform expression in breast cancer tissues. The effects of MSI2a and MSI2b on TNBC cells were assayed in vitro and in vivo. RNA immunoprecipitation (RIP) and RNA sequencing were performed to identify the potential mRNA targets of MSI2a, and RIP and luciferase analyses were used to confirm the mRNA targets of MSI2. Results MSI2 expression in TNBC tissues was significantly downregulated compared to that in normal tissues. In TNBC, MSI2a expression was associated with poor overall survival of patients. MSI2a overexpression in vitro and in vivo inhibited TNBC cell invasion as well as extracellular signal-regulated kinase 1/2 (ERK1/2) activity. However, MSI2b overexpression had no significant effects on TNBC cell migration. Mechanistically, MSI2a expression promoted TP53INP1 mRNA stability by its interaction with the 3′-untranslated region of TP53INP1 mRNA. Furthermore, TP53INP1 knockdown reversed MSI2a-induced suppression of TNBC cell invasion, whereas ectopic expression of TP53INP1 and inhibition of ERK1/2 activity blocked MSI2 knockdown-induced TNBC cell invasion. Conclusions The current study demonstrated that MSI2a is the predominant functional isoform of MSI2 proteins in TNBC, that its downregulation is associated with TNBC progression and poor prognosis and that MSI2a expression inhibited TNBC invasion by stabilizing TP53INP1 mRNA and inhibiting ERK1/2 activity. Overall, our study provides new insights into the isoform-specific roles of MSI2a and MSI2b in the tumor progression of TNBC, allowing for novel therapeutic strategies to be developed for TNBC.

MSI2 regulates NLK-mediated EMT and PI3K/AKT/mTOR pathway to promote pancreatic cancer progression

Musashi2 promotes the progression of pancreatic cancer through a novel ISYNA1‐p21/ZEB‐1 pathway

Supplementary Figures 1-3 from the Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer

Musashi2 promotes the proliferation and migration of colorectal cancer by down-regulating Numb protein

Musashi-1 Enhances Glioblastoma Cell Migration and Cytoskeletal Dynamics through Translational Inhibition of Tensin3

Activation of the Wnt pathway through Wnt2 promotes metastasis in pancreatic cancer.

Cooperation Of Musashi-2, Numb, Mdm2, And P53 In Drug Resistance And Malignant Biology Of Pancreatic Cancer

MSI2 Knockdown Represses Extrahepatic Cholangiocarcinoma Growth and Invasion by Inhibiting Epithelial-Mesenchymal Transition.

Effect of RNA-binding Protein MSI2 Deficiency on Progression in Triple-Negative Breast Cancer Via Stabilizing TP53INP1.

MSI2-TGF-β/TGF-β R1/SMAD3 positive feedback regulation in glioblastoma

RNA-binding Protein MSI2 Isoforms Expression and Regulation in Progression of Triple-Negative Breast Cancer

A Novel Regulatory Axis of MSI2-AGO2/miR-30a-3p-CGRRF1 Drives Cancer Chemoresistance by Upregulating the KRAS/ERK Pathway

MLPH regulates EMT in pancreatic adenocarcinoma through the PI3K-AKT signaling pathway

Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3–Mmp9 pathway

Kindlin-2 enhances c-Myc translation through association with DDX3X to promote pancreatic ductal adenocarcinoma progression

EZH2-Mediated Microrna-139-5p Regulates Epithelial-Mesenchymal Transition and Lymph Node Metastasis of Pancreatic Cancer.

Msi-1 is a Predictor of Survival and a Novel Therapeutic Target in Colon Cancer

Transformation of the intestinal epithelium by the MSI2 RNA-binding protein

CTDSPL2 promotes the progression of non-small lung cancer through PI3K/AKT signaling via JAK1

MAL2 Interacts with IQGAP1 to Promote Pancreatic Cancer Progression by Increasing ERK1/2 Phosphorylation

Transcription factor FOXF2 promotes the development and progression of pancreatic cancer by targeting MSI2